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Bone mineral density (BMD) is a multi-factorial phenotype determined by factors such as 
physical activity, diet and a sizeable genetic component. Athletic populations tend to possess 
higher BMD than non-athletes due to a larger volume of exercise completed. Despite this, some 
endurance runners can possess low BMD and/or suffer stress fractures, which can have 
negative impacts on their health and performance. Therefore, we hypothesised that elite 
endurance runners would possess a genotype associated with enhanced BMD and a reduced 
risk of injury, resulting in less training interruption and greater potential success. The study 
compared the genotype and allele frequencies of 5 genetic variants associated with BMD 
(LRP5 rs3736228, TNFRSF11B rs4355801, VDR rs2228570, WNT16 rs3801387, AXIN1 
rs9921222) in elite (men < 2 h 30 min, n = 110; women < 3 h 00 min, n = 98) and sub-elite 
(men 2 h 30 min – 2 h 45 min, n = 181; women 3 h 00 min – 3 h 15 min, n = 67) marathon 
runners with those of a non-athlete control population (n = 474). We also investigated whether 
marathon personal best time was associated with a more “advantageous” BMD genotype. 
Congruent with our hypothesis, the “risk” T allele for the AXIN1 rs9921222 polymorphism was 
5% more frequent in the control group than in sub-elites (P = 0.030, χ2 = 4.69) but no further 
differences were observed for this variant (P ≥ 0.083, χ2 ≤ 4.98). WNT16 rs3801387 genotype 
frequency differed between athletes and controls (P = 0.002, χ2 = 12.02) and elites vs controls 
(P = 0.008, χ2 = 9.72), as did allele frequency. However, contrary to our hypothesis, it was the 
“risk” A allele that was ~5% more frequent in athletes than controls. Similarly, when 
combining data from all 5 variants, the athletes had a lower Total Genotype Score than controls 
(53.6 vs 65.7; P ≤ 0.001), again suggesting greater genetic susceptibility to bone injury in 
athletes. Personal best times were not associated with genotype in any comparison. These 
results suggest that high-level endurance runners do not benefit from genetic resistance to bone 
injury and a resulting ability to sustain large training volumes, contradicting our hypothesis. 
High-level endurance runners appear to be at a higher risk of bone injury from a genetic 
perspective, for as yet unexplained reasons, although large inter-individual differences in 
genetic risk exist.  
 
